ClinicalTrials.gg
CompletedNCT02193828Updated Oct 5, 2017Results posted

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

A Phase 2 interventional study of Collagenase clostridium histolyticum and Placebo in Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.

Enrollment
9th of 17
76 · median 76
Started
2014
the only one that year
Phase 2
Only one
of the 17
Registered
13th of 17
by date
Lead sponsor
6 of 17
Endo Pharmaceuticals

Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 9th largest by enrollment, is the only one that started in 2014, is the only one in phase 2, and was the 13th registered.

Dupuytren Contracture

78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.

Browse Dupuytren Contracture studies →

Open to participants now

None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Microbial Collagenase in Dupuytren Contracture as a file.
02

Study summary

The objectives of this study are to assess the safety and effectiveness of AA4500 in treating palmar Dupuytren's disease nodules.

Read the detailed description

Approximately 13 sites in the United States and Australia, approximately 90 study subjects.

After all pre-injection procedures are completed on day 1, eligible men and women will be randomized in a 1:1:1 ratio to dose group and then in a 4:1 ratio to treatment group. Study drug will be administered into a palmar nodule located on the selected hand.

AA4500 (collagenase clostridium histolyticum) 3 doses (low, medium, and high) after reconstitution with sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride). Each dose of study drug will be injected into the nodule. The injection will be administered in 3 different volumes according to randomization.

Placebo after reconstitution with sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride). Each dose of study drug will be injected into the nodule. The injection will be administered in 3 different volumes according to randomization.

Follow up visits for the evaluation of safety and efficacy will be required for all subjects on days 8, 29, and 57.

03

Conditions studied

  • Dupuytren's Disease

Browse trials for

Keywords

  • Dupuytren's nodules
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide a signed and dated
  2. Be a man or woman ≥ 18 years of age
  3. Have a diagnosis of Dupuytren's disease AND have at least one palmar nodule on the selected hand that is:

    1. Palpable
    2. Measures between 0.5 cm and 2.0 cm in length and between 0.5 cm and 2.0 cm in width using hand-held calipers n
    3. Not directly associated with a Dupuytren's cord
  4. Have a negative urine pregnancy test at screening and before injection of study drug and be using a highly effective (ie, \< 1% failure rate) method as judged by the investigator (eg, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for the duration of the study or be surgically sterile (if female of ); or be a female (no menses for at least 1 year or hysterectomy)
  5. Be able to comply with the study visit schedule as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Received injections (eg, tri-amcinolone acetonide) on the selected nodule within 3 months before administration of study drug
  2. Has a chronic muscular, neurological, or neuromuscular disorder that affects the hands
  3. Has a known systemic allergy to collagenase or any other of AA4500
  4. Has received any collagenase treatments (eg, Santyl® ointment and/or XIAFLEX®/XIAPEX®) within 30 days before injection of study drug in the hand selected for treatment
  5. Is currently receiving or plans to receive anticoagulant medication or has received anticoagulant medication (except for ≤ 150 mg aspirin daily) within 7 days before injection of study drug
  6. Has a known recent history of stroke, bleeding, or other medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  7. Received an drug within 30 days before injection of study drug
  8. Is pregnant or intends on becoming pregnant during the study or is breastfeeding a child
  9. Has any medical history or condition(s), including conditions that affect the hands, that would, in the opinion of the investigator, substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives of the study
  10. Had surgery on the selected hand within 3 months before the screening visit
  11. Has jewelry on the hand to be treated that cannot be removed
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    AA4500 0.25 mg

    Collagenase clostridium histolyticum, single 0.25 mg injection

    Biological: Collagenase clostridium histolyticum

  • Experimental
    AA4500 0.40 mg

    Collagenase clostridium histolyticum, single 0.40 mg injection

    Biological: Collagenase clostridium histolyticum

  • Experimental
    AA4500 0.60 mg

    Collagenase clostridium histolyticum, single 0.60 mg injection

    Biological: Collagenase clostridium histolyticum

  • Placebo comparator
    Placebo

    Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements

    Percent change from baseline in surface area and volume of the treated nodule was determined from hand-held caliper measurements of the length and width of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.

    Time frame: Baseline, Day 57

Secondary outcomes

  1. Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Ultrasound

    Percent change from baseline in surface area and volume of the treated nodule was determined from ultrasound measurements of the length, width, and depth of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.

    Time frame: Baseline, Day 57

  2. Change From Baseline in Consistency of the Treated Nodules at Day 57

    Investigators determined the consistency of the nodule through palpitation using a 5-point scale: 5 = hard (solid), 4 = firm throughout, 3 = moderate firmness, 2 = soft, and 1 = non-palpable. The change scores could range from +4 (greatest worsening in consistency) to -4 (greatest improvement in consistency); a negative change from baseline value reflects improvement from baseline (softening) while a positive value reflects worsening.

    Time frame: Baseline, Day 57

  3. Percent Change From Baseline in Hardness of the Treated Nodule at Day 57

    A durometer was used to assess nodule hardness on a scale of 0 (soft) to 100 (hard). Percent change = 100\*(Day 57 hardness - baseline hardness)/baseline hardness. A negative value represents the improvement from baseline (softening) while a positive value represents worsening.

    Time frame: Baseline, Day 57

  4. Change From Baseline in Nodular Pain of the Treated Nodule at Day 57

    After the nodule was squeezed using a dynamometer, subjects were asked to rate the amount of pain they felt on an 11-point visual analog scale (VAS) from 0 (no pain or discomfort) to 10 (extreme pain or discomfort). A negative change from baseline value reflects improvement from baseline (less pain) while a positive value reflects worsening.

    Time frame: Baseline, Day 57

  5. Investigator Global Assessment of Improvement With Treatment

    Investigators were asked to determine the degree of improvement in the subject's treated nodule compared with screening on a 7-point scale: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Day 57

  6. Subject Satisfaction With Treatment

    Subjects were asked to rate their satisfaction with treatment on a 5-point scale: 1 = very satisfied, 2 = quite satisfied, 3 = neither satisfied nor dissatisfied, 4 = quite dissatisfied, and 5 = very dissatisfied.

    Time frame: Day 57

  7. Composite Responder Analysis

    A composite responder is a subject who had an improved assessment \[values of 1 (very much improved), 2 (much improved), or 3 (minimally improved)\] on the investigator global assessment and had a satisfied assessment \[values of 1 (very satisfied) or 2 (quite satisfied)\] on the subject assessment.

    Time frame: Day 57

07

Results

Posted Jul 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Started18182317
Completed18182216
Not completed0011
Withdrew: Withdrawal by subject0011

Outcome measures

PrimaryPercent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements

Percent change from baseline in surface area and volume of the treated nodule was determined from hand-held caliper measurements of the length and width of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.

Time frame:
Baseline, Day 57
Reported as:
Mean · percentage of change
Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements
percentage of changeAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Surface Area-81.61 ± 20.251-80.11 ± 21.459-58.30 ± 29.849-41.76 ± 32.445
Volume-89.03 ± 15.016-87.58 ± 16.372-68.15 ± 33.859-49.13 ± 36.736
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · ANOVA · p = <.0001
  • AA4500 0.60 mg vs Placebo · ANOVA · p = <.0001
  • AA4500 0.40 mg vs Placebo · ANOVA · p = <.0001
  • AA4500 0.25 mg vs Placebo · ANOVA · p = .0713
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · ANOVA · p = .0002
  • AA4500 0.60 mg vs Placebo · ANOVA · p = .0001
  • AA4500 0.40 mg vs Placebo · ANOVA · p = .0001
  • AA4500 0.25 mg vs Placebo · ANOVA · p = .0446
SecondaryPercent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Ultrasound

Percent change from baseline in surface area and volume of the treated nodule was determined from ultrasound measurements of the length, width, and depth of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.

Time frame:
Baseline, Day 57
Reported as:
Mean · percentage of change
Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Ultrasound
percentage of changeAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Surface Area-34.23 ± 41.353-19.37 ± 39.658-10.30 ± 41.696-4.54 ± 54.784
Volume-40.99 ± 46.612-13.01 ± 68.804-9.52 ± 60.156-7.19 ± 69.877
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · ANOVA · p = .2431
  • AA4500 0.60 mg vs Placebo · ANOVA · p = .0625
  • AA4500 0.40 mg vs Placebo · ANOVA · p = .3409
  • AA4500 0.25 mg vs Placebo · ANOVA · p = .7040
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · ANOVA · p = 0.3556
  • AA4500 0.60 mg vs Placebo · ANOVA · p = .1275
  • AA4500 0.40 mg vs Placebo · ANOVA · p = .7883
  • AA4500 0.25 mg vs Placebo · ANOVA · p = .9123
SecondaryChange From Baseline in Consistency of the Treated Nodules at Day 57

Investigators determined the consistency of the nodule through palpitation using a 5-point scale: 5 = hard (solid), 4 = firm throughout, 3 = moderate firmness, 2 = soft, and 1 = non-palpable. The change scores could range from +4 (greatest worsening in consistency) to -4 (greatest improvement in consistency); a negative change from baseline value reflects improvement from baseline (softening) while a positive value reflects worsening.

Time frame:
Baseline, Day 57
Reported as:
Mean · units on a scale
Change From Baseline in Consistency of the Treated Nodules at Day 57
units on a scaleAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Change From Baseline in Consistency of the Treated Nodules at Day 57-1.9 ± 0.93-1.9 ± 1.05-1.2 ± 1.10-0.3 ± 0.96
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · Kruskal-Wallis · p = .0002
  • AA4500 0.60 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = <.0001
  • AA4500 0.40 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .0002
  • AA4500 0.25 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .0139
SecondaryPercent Change From Baseline in Hardness of the Treated Nodule at Day 57

A durometer was used to assess nodule hardness on a scale of 0 (soft) to 100 (hard). Percent change = 100\*(Day 57 hardness - baseline hardness)/baseline hardness. A negative value represents the improvement from baseline (softening) while a positive value represents worsening.

Time frame:
Baseline, Day 57
Reported as:
Mean · percentage of change
Percent Change From Baseline in Hardness of the Treated Nodule at Day 57
percentage of changeAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Percent Change From Baseline in Hardness of the Treated Nodule at Day 57-17.05 ± 15.584-30.40 ± 24.930-17.87 ± 22.2654.80 ± 23.959
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · ANOVA · p = .0004
  • AA4500 0.60 mg vs Placebo · ANOVA · p = .0075
  • AA4500 0.40 mg vs Placebo · ANOVA · p = <.0001
  • AA4500 0.25 mg vs Placebo · ANOVA · p = .0031
SecondaryChange From Baseline in Nodular Pain of the Treated Nodule at Day 57

After the nodule was squeezed using a dynamometer, subjects were asked to rate the amount of pain they felt on an 11-point visual analog scale (VAS) from 0 (no pain or discomfort) to 10 (extreme pain or discomfort). A negative change from baseline value reflects improvement from baseline (less pain) while a positive value reflects worsening.

Time frame:
Baseline, Day 57
Reported as:
Mean · units on a scale
Change From Baseline in Nodular Pain of the Treated Nodule at Day 57
units on a scaleAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Change From Baseline in Nodular Pain of the Treated Nodule at Day 57-0.8 ± 1.97-1.6 ± 2.21-1.7 ± 2.57-0.5 ± 1.77
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · ANOVA · p = .3135
  • AA4500 0.60 mg vs Placebo · ANOVA · p = .7249
  • AA4500 0.40 mg vs Placebo · ANOVA · p = .1573
  • AA4500 0.25 mg vs Placebo · ANOVA · p = .1234
SecondaryInvestigator Global Assessment of Improvement With Treatment

Investigators were asked to determine the degree of improvement in the subject's treated nodule compared with screening on a 7-point scale: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Day 57
Reported as:
Mean · units on a scale
Investigator Global Assessment of Improvement With Treatment
units on a scaleAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Investigator Global Assessment of Improvement With Treatment1.7 ± 0.841.7 ± 0.752.5 ± 1.103.0 ± 1.15
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · Kruskal-Wallis · p = .0006
  • AA4500 0.60 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .0014
  • AA4500 0.40 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .0012
  • AA4500 0.25 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .1298
SecondarySubject Satisfaction With Treatment

Subjects were asked to rate their satisfaction with treatment on a 5-point scale: 1 = very satisfied, 2 = quite satisfied, 3 = neither satisfied nor dissatisfied, 4 = quite dissatisfied, and 5 = very dissatisfied.

Time frame:
Day 57
Reported as:
Mean · units on a scale
Subject Satisfaction With Treatment
units on a scaleAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Subject Satisfaction With Treatment1.5 ± 0.791.6 ± 0.852.3 ± 1.172.8 ± 1.34
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · Kruskal-Wallis · p = .0048
  • AA4500 0.60 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .0034
  • AA4500 0.40 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .0079
  • AA4500 0.25 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = .3216
SecondaryComposite Responder Analysis

A composite responder is a subject who had an improved assessment \[values of 1 (very much improved), 2 (much improved), or 3 (minimally improved)\] on the investigator global assessment and had a satisfied assessment \[values of 1 (very satisfied) or 2 (quite satisfied)\] on the subject assessment.

Time frame:
Day 57
Reported as:
Number · participants
Composite Responder Analysis
participantsAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
Responder: Yes1416126
Responder: No421010
Statistical analysis
  • AA4500 0.60 mg vs AA4500 0.40 mg vs AA4500 0.25 mg vs Placebo · Fisher Exact · p = .0065
  • AA4500 0.60 mg vs Placebo · Fisher Exact · p = .0349
  • AA4500 0.40 mg vs Placebo · Fisher Exact · p = .0033
  • AA4500 0.25 mg vs Placebo · Fisher Exact · p = .3423

Adverse events

Collected over Adverse events were collected from enrollment through the end of the study (Day 57).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.60 mg—0/18 (0%)17/18 (94.4%)
AA4500 0.40 mg—0/18 (0%)18/18 (100%)
AA4500 0.25 mg—0/22 (0%)21/22 (95.5%)
Placebo—0/17 (0%)7/17 (41.2%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventAA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlacebo
ContusionInjury, poisoning and procedural complications9/189/1813/221/17
Local swellingGeneral disorders10/187/188/223/17
Pain in extremityMusculoskeletal and connective tissue disorders7/1810/1810/221/17
Injection site bruisingGeneral disorders6/184/185/220/17
Axillary painGeneral disorders4/181/186/220/17
Injection site swellingGeneral disorders0/184/185/220/17
Injection site painGeneral disorders2/184/184/220/17
Injection site pruritusGeneral disorders2/183/182/221/17
Injection site oedemaGeneral disorders2/180/182/220/17
PruritusSkin and subcutaneous tissue disorders1/182/182/220/17

Baseline characteristics

Analysis based on Safety population; all randomized subjects who received an injection of study medication. One subject did not receive study medication.

Age, Categorical
Age, Categorical(Participants)AA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlaceboTotal
<=18 years00000
Between 18 and 65 years1312161152
>=65 years566623
Age, Continuous
Age, Continuous(years)AA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlaceboTotal
Median62.0 (41 to 84)60.0 (37 to 75)57.0 (32 to 73)58.0 (45 to 73)58.0 (32 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlaceboTotal
Female61011734
Male128111041
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlaceboTotal
Hispanic or Latino11114
Not Hispanic or Latino1717211671
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlaceboTotal
American Indian or Alaska Native01001
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1817221774
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)AA4500 0.60 mgAA4500 0.40 mgAA4500 0.25 mgPlaceboTotal
United States1210141248
Australia688527
08

Study locations

11 sites
  • Tucson Orthopaedic Institute
    Tucson, Arizona 85712, United States
  • CORE Orthopaedic Medical Center
    Encinitas, California 92024, United States
  • Marin Endocrine Care & Research, Inc.
    Greenbrae, California 94904, United States
  • Brigid Freyne, MD, Inc.
    Murrieta, California 92563, United States
  • Indiana Hand to Shoulder Center
    Indianapolis, Indiana 46260, United States
  • State University of New York
    Stony Brook, New York 11794, United States
  • OrthoCarolina Research Institute, Inc.
    Charlotte, North Carolina 28207, United States
  • Orthopedic and Reconstructive Center
    Oklahoma City, Oklahoma 73109, United States
  • Blair Orthopedic Associates, Inc.
    Altoona, Pennsylvania 16602, United States
  • Brisbane Hand & Upper Limb Clinic
    Brisbane, Queensland 4000, Australia
  • Houston Medical
    Kippa Ring, Queensland 4021, Australia
09

References and documents

Publications

  • Costas B, Coleman S, Kaufman G, James R, Cohen B, Gaston RG. Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial. BMC Musculoskelet Disord. 2017 Aug 30;18(1):374. doi: 10.1186/s12891-017-1713-z. PubMed 28854973 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2014
First posted
Jul 18, 2014
Start
Jul 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Jul 7, 2015
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02193828
Responsible party
Sponsor
First posted
Jul 18, 2014
Start date
Jul 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jul 7, 2015
Last update
Oct 5, 2017

Study contacts

Veronica Urdaneta, MD MPH
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion